arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked

Unlocking Commercial Potential in Pharma Pipelines

Planning early for long-term success

San Diego |
Speakers include:
Donato Paolo Mancini

Donato Paolo Mancini

Financial Times

Overview

In an increasingly competitive, fast-paced and dynamic commercial environment, pharma companies must learn to act early to unlock the market potential of their products. Effective planning and strategic decisions are needed from the outset to tackle the challenges of development and launch. What does it take to enhance and communicate the value of your product, secure funding and access commercial opportunities?  How do you meet changing stakeholder expectations and customer demands?

Hosted by the Financial Times and Syneos Health, this breakfast meeting will bring together senior executives from biopharmaceutical companies to consider the benefits and challenges of a more active commercial strategy early in the product cycle.  Guests will discuss how to understand and manage the risks, access the opportunities and accelerate progress towards successful commercialization. 

fallback
fallback Add to my Calendar 10/10/2019 07:30:0010/10/2019 10:00:00falseUnlocking Commercial Potential in Pharma PipelinesIn an increasingly competitive, fast-paced and dynamic commercial environment, pharma companies must learn to act early to unlock the market potential of their products. Effective planning and strategic decisions are needed from the outset to tackle the challenges of development and launch. What does it take to enhance and communicate the value of your product, secure funding and access commercial opportunities?  How do you meet changing stakeholder expectations and customer demands?Hosted by the Financial Times and Syneos Health, this breakfast meeting will bring together senior executives from biopharmaceutical companies to consider the benefits and challenges of a more active commercial strategy early in the product cycle.  Guests will discuss how to understand and manage the risks, access the opportunities and accelerate progress towards successful commercialization. Unlocking-Commercial-Potential-in-Pharma-Pipelinesfb399b1d1ccc3cae75579f46052026aeMM/DD/YYYY

Agenda - 10th Oct

  • 7:30am
    Guest arrivals
  • 7:45am
    Opening remarks from FT chair
  • 7:50am
    Breakfast and discussion
  • 9:25am
    Closing remarks from FT chair
  • 9:30am
    End of breakfast

Chair (1)

Donato Paolo Mancini

Donato Paolo Mancini

Reporter
Financial Times

Donato Paolo Mancini covers companies at the Financial Times, with a particular interest in R&D, pharma and regulation. His reporting is aimed at exploring how the social contract between the public, research and regulators can best address unmet need, and how companies can aim to be profitable while ensuring access is as wide as possible. He joined the FT in 2019 having previously worked at the Wall Street Journal and Dow Jones, where he also wrote about pharma among other topics. His first reporting assignment was in Istanbul, covering the Gezi Park protests of 2013, and he’s covered major corporate and news events since.

See bio fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

In association with (1)

Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. The Syneos Health Reputation & Risk Management Practice is a group of communications counselors on the speed-dials of life-science leaders in need of solutions for the industry’s most sensitive, emerging challenges. The group is known for proven, evidence based strategies to address topics including the affordability of medicines, compassionate use, safety, litigation and access barriers. Our counsel and subject matter expertise is gained from decades of experience serving in the U.S. Food & Drug Administration, The Centers for Medicare & Medicaid Services, Congress, healthcare consulting, legal communications, public health and crisis communications. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com

Venue

La Valencia Hotel
1132 Prospect St.
La Jolla
 San Diego CA 92037
Tel: +1 855-476-6870
fallback

CONTACT US

Ciaran Larkin
Content Manager
Financial Times Live